Neuropediatrics, Table of Contents Neuropediatrics 1997; 28(1): 33-36DOI: 10.1055/s-2007-973663 Original articles © Hippokrates Verlag GmbH StuttgartExpression Studies of CLN3 ProteinW. Kaczmarski, E. Kida1 , A. Lach1 , R. Rubenstein2 , N. Zhong3 , K. E. Wisniewski1 1Departments of Pathological Neurobiology, NYS Institute for Basic Research in Developmental Disabilities, S.I., NY, USA 2Departments of Molecular Neurovirology, NYS Institute for Basic Research in Developmental Disabilities, S.I., NY, USA 3Departments of Human Genetics, NYS Institute for Basic Research in Developmental Disabilities, S.I., NY, USA Recommend Article Abstract PDF Download(opens in new window) Buy Article(opens in new window) Abstract Expression of the gene for Batten disease (CLN3) was studied in Escherichia coil and in a cell-free rabbit reticulocyte expression systems. A full-length recombinant fusion CLN3 protein was not produced in the bacterial systems used. However, both N-terminal fragment encompassing 246 amino acids and short C-terminal fragment containing 428-438 amino acids of the CLN3 protein were successfully overexpressed in bacteria. Further studies showed that the C-terminal sequence of the CLN3 protein corresponding to the 356-438 amino acid residues was responsible for inhibition of protein synthesis in bacteria. The full-length CLN3 gene product was readily synthesized in vitro in the cell-free rabbit reticulocyte expression system. The product obtained, corresponding to core CLN3 protein, showed an approximate molecular weight of 43 kDa. Immunoprecipitation of this product with pAb to 4-19 amino acids of the CLN3 protein allows us to suggest that CLN3 protein translation starts at Met-1. Key words Batten disease - CLN3 - Expression systems - Reticulocytes PDF (696 kb)